Niagen Bioscience (NAGE) Cash from Investing Activities (2011 - 2026)
Niagen Bioscience (NAGE) reported Cash from Investing Activities of $5.2 million for Q1 2026, up 16490.62% year-over-year from N/an in Q1 2025, and up 5293.07% quarter-over-quarter from -$101000.0 in Q4 2025.
Niagen Bioscience (NAGE) Cash from Investing Activities (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 14 years of Cash from Investing Activities data on file, last reported at $5.2 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $5.2 million, up 16490.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 million (up 3820.15% YoY), and the FY2025 annual result was -$292000.0, down 104.2% from the prior year.
- Cash from Investing Activities climbed to $5.2 million in Q1 2026 per NAGE's latest filing, from -$101000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $5.2 million in Q1 2026 and troughed at -$172000.0 in Q4 2022.
- A 5-year average of $254882.4 and a median of -$32000.0 in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities sank 8500.0% in 2022, then surged 16490.62% in 2026.
- A 5-year view of Cash from Investing Activities shows it stood at -$172000.0 in 2022, then soared by 87.79% to -$21000.0 in 2023, then sank by 228.57% to -$69000.0 in 2024, then sank by 46.38% to -$101000.0 in 2025, then soared by 5293.07% to $5.2 million in 2026.
- Business Quant data shows NAGE's Cash from Investing Activities at $5.2 million in Q1 2026, -$101000.0 in Q4 2025, and -$24000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | Niagen Bioscience | 277.31 Mn | 210.76 Mn | 19.98 Mn | 5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.25 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | -101,000.00 |
| Dec 31, 2025 | -101,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | -135,000.00 |
| Jun 30, 2025 | -135,000.00 |
| Mar 31, 2025 | -32,000.00 |
| Mar 31, 2025 | -32,000.00 |
| Dec 31, 2024 | -69,000.00 |
| Dec 31, 2024 | -69,000.00 |
| Sep 30, 2024 | -21,000.00 |
| Sep 30, 2024 | -21,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Dec 31, 2023 | -21,000.00 |
| Dec 31, 2023 | -21,000.00 |